Adial Pharmaceuticals Inc... (ADIL)
Adial Pharmaceuticals Statistics
Share Statistics
Adial Pharmaceuticals has 6.57M shares outstanding. The number of shares has increased by 55.31% in one year.
| Shares Outstanding | 6.57M |
| Shares Change (YoY) | 55.31% |
| Shares Change (QoQ) | 1.54% |
| Owned by Institutions (%) | 0.06% |
| Shares Floating | 6.46M |
| Failed to Deliver (FTD) Shares | 6.69K |
| FTD / Avg. Volume | 0.81% |
Short Selling Information
The latest short interest is 78.88K, so 1.22% of the outstanding shares have been sold short.
| Short Interest | 78.88K |
| Short % of Shares Out | 1.22% |
| Short % of Float | 1.24% |
| Short Ratio (days to cover) | 0.65 |
Valuation Ratios
The PE ratio is -1.42 and the forward PE ratio is -0.59. Adial Pharmaceuticals's PEG ratio is 0.02.
| PE Ratio | -1.42 |
| Forward PE | -0.59 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 4.62 |
| P/FCF Ratio | -2.71 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Adial Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.16, with a Debt / Equity ratio of 0.
| Current Ratio | 4.16 |
| Quick Ratio | 4.16 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.64M |
| Employee Count | 5 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -42.62% in the last 52 weeks. The beta is 1.26, so Adial Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | -42.62% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 43.8 |
| Average Volume (20 Days) | 830.41K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -8.28M |
| Net Income | -13.2M |
| EBITDA | -8.28M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.71 |
Balance Sheet
The company has 3.75M in cash and 0 in debt, giving a net cash position of 3.75M.
| Cash & Cash Equivalents | 3.75M |
| Total Debt | 0 |
| Net Cash | 3.75M |
| Retained Earnings | -82M |
| Total Assets | 5.04M |
| Working Capital | 3.08M |
Cash Flow
In the last 12 months, operating cash flow was -6.92M and capital expenditures 0, giving a free cash flow of -6.92M.
| Operating Cash Flow | -6.92M |
| Capital Expenditures | 0 |
| Free Cash Flow | -6.92M |
| FCF Per Share | -0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ADIL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ADIL is $8, which is 1042.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 1042.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 7, 2023. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 7, 2023 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -24.87 |
| Piotroski F-Score | 1 |